BeOne Medicines' shares [HKG: 6160] rose 2.3 percent as of 9.33 a.m. after the multinational oncology firm reported its net profit more than quadrupled to CNY2.8 billion (USD417 million) in the third quarter from a year earlier, while revenue jumped 27% to CNY12.8 billion (USD1.9 billion).